Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
  • Alerts
  • Podcasts
  • Subscriptions

Does PDE4 inhibition improve alveolarisation in hyperoxia-exposed immature rodents?

C. Méhats, J. Bourbon, P-H. Jarreau
European Respiratory Journal 2009 33: 1236; DOI: 10.1183/09031936.00002809
C. Méhats
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Bourbon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P-H. Jarreau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

To the Editors:

A recent European Respiratory Journal article by Woyda et al. 1 discussed the effect of a phosphodiesterase (PDE)4 inhibitor, cilomilast, on alveolarisation in mouse pups exposed to hyperoxia. Woyda et al. 1 claimed in the title and concluded in the text that this treatment had the beneficial effect of preventing hyperoxia-induced impairment of alveolarisation, and proposed that PDE4 inhibition could represent a potential new therapy for bronchopulmonary dysplasia. We think that this conclusion overstated the study design and the obtained results. Although we used a different inhibitor (rolipram), our recently published study indicated that PDE4 inhibition did not enhance alveolarisation in rat pups exposed to hyperoxia, and may even directly affect alveolarisation in rat pups exposed to room air 2.

The latter finding leads to the first and major criticism that can be aimed at the article of Woyda et al. 1, namely the lack of an appropriate control group to study the effect of the PDE4 inhibitor on normal alveolarisation as evaluated by administering it to air-exposed pups. As a consequence of the lack of this control group, two of the main effects of PDE4 inhibition in rodent pups that we reported (impairment of weight gain and disturbed alveolarisation) were not evaluated by Woyda et al. 1. The effect on weight gain may have been less than that observed by us 2 and others 3, as Woyda et al. 1 studied mice instead of rats and administered the PDE4 inhibitor later in life. But studying the effects of PDE4 inhibition on normal alveolarisation may have revealed crucial changes and is clearly missing.

A second major concern about the study of Woyda et al. 1 is an overstatement of the reported data. Figure 5 of their paper shows an obvious rarefaction of alveoli under hyperoxia, but the figure does not show any improvement of alveolarisation after PDE4 inhibition. The morphometric determinations used are very simplistic and rough compared with data that can be obtained with these methods and usually published in the field 4. Moreover, Woyda et al. 1 did not demonstrate any biologically significant beneficial effect of PDE4 inhibition on hyperoxia-induced impairment of alveolarisation; although the mean linear intercept was statistically different between hyperoxia and hyperoxia+cilomilast groups, the difference was extremely weak (a 4% reduction only!) and the mean linear intercept remained considerably increased as compared to that in animals maintained under normoxia (plus 78% and plus 70% in hyperoxia and hyperoxia+cilomilast groups, respectively). This minute variation, even if statistically significant, cannot be considered biologically relevant and does not allow the authors to claim a beneficial effect of cilomilast. The total airspace changes were in the same range of very weak variations (roughly 118% of the baseline value under hyperoxia and 114% with cilomilast). Consistent with this very weak, if actual, effect on alveolarisation, there was no effect on dynamic compliance. Performing an in-depth analysis of alveolarisation in rat pups in our previous study according to the criteria established by Weibel and Cruz-Orvive 4, we found no beneficial effect of PDE4 inhibition on alveolarisation. Furthermore, PDE4 inhibition under air induced a decrease in alveolar surface area and radial alveolar count 2, the interpretation of which was rendered difficult by the impairment of weight gain of pups treated with PDE4 inhibitors, because undernutrition and impaired weight gain can modify lung morphometric parameters.

Considering these remarks and the present state of development of phosphodiesterase 4 inhibitors, to claim for enhanced alveolarisation by phosphodiesterase 4 inhibition in a bronchopulmonary dysplasia model appears to be an overstatement. It is at least premature, if not erroneous and dangerous, to propose phosphodiesterase 4 inhibition as a new treatment of bronchopulmonary dysplasia on the basis of data reported in the paper by Woyda et al. 1.

Statement of interest

None declared.

    • © ERS Journals Ltd

    References

    1. ↵
      Woyda K, Koebrich S, Reiss I, et al. Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia. Eur Respir J 2009;33:861–870.
      OpenUrlAbstract/FREE Full Text
    2. ↵
      Mehats C, Franco-Montoya ML, Boucherat O, et al. Effects of phosphodiesterase 4 inhibition on alveolarization and hyperoxia toxicity in newborn rats. PLoS ONE 2008;3:e3445
      OpenUrlCrossRefPubMed
    3. ↵
      de Visser YP, Walther FJ, Laghmani EH, van Wijngaarden S, Nieuwland K, Wagenaar GT. Phosphodiesterase 4 inhibition attenuates pulmonary inflammation in neonatal lung injury. Eur Respir J 2007;31:633–644.
      OpenUrlCrossRefPubMedWeb of Science
    4. ↵
      Weibel ER, Cruz-Orive LM. Morphometric methods. In: Crystal RG, West JB, Weibel ER, Barnes PJ, eds. The Lung: Scientific Foundations. Philadelphia, Lippincott-Raven, 1997; pp. 333–344
    View Abstract
    PreviousNext
    Back to top
    View this article with LENS
    Vol 33 Issue 5 Table of Contents
    European Respiratory Journal: 33 (5)
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Does PDE4 inhibition improve alveolarisation in hyperoxia-exposed immature rodents?
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    Print
    Alerts
    Sign In to Email Alerts with your Email Address
    Citation Tools
    Does PDE4 inhibition improve alveolarisation in hyperoxia-exposed immature rodents?
    C. Méhats, J. Bourbon, P-H. Jarreau
    European Respiratory Journal May 2009, 33 (5) 1236; DOI: 10.1183/09031936.00002809

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    Does PDE4 inhibition improve alveolarisation in hyperoxia-exposed immature rodents?
    C. Méhats, J. Bourbon, P-H. Jarreau
    European Respiratory Journal May 2009, 33 (5) 1236; DOI: 10.1183/09031936.00002809
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • Statement of interest
      • References
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Testing bronchodilator responsiveness
    • Testing bronchodilator responsiveness
    • Pharmacodynamics and pharmacokinetics in nontuberculosis mycobacteria infections
    Show more Correspondence

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERJ

    • Journal information
    • Editorial board
    • Reviewers
    • CME
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Submit a manuscript
    • ERS author centre

    For readers

    • Alerts
    • Subjects
    • Collections
    • Podcasts
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN:  0903-1936
    Online ISSN: 1399-3003

    Copyright © 2019 by the European Respiratory Society